
Barry Choobin
Examiner (ID: 2847)
| Most Active Art Unit | 2625 |
| Art Unit(s) | 2623, 2721, 2621, 2624, 2625 |
| Total Applications | 321 |
| Issued Applications | 267 |
| Pending Applications | 27 |
| Abandoned Applications | 27 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16053251
[patent_doc_number] => 20200188480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 16/805370
[patent_app_country] => US
[patent_app_date] => 2020-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11248
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805370
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/805370 | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient | Feb 27, 2020 | Issued |
Array
(
[id] => 17548133
[patent_doc_number] => 20220119474
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/431867
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16737
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/431867 | PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF | Feb 18, 2020 | Abandoned |
Array
(
[id] => 17563164
[patent_doc_number] => 20220127313
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => POLYPEPTIDES FOR RESTORING ENDOTHELIAL FUNCTION AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/430365
[patent_app_country] => US
[patent_app_date] => 2020-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430365
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/430365 | Polypeptides for restoring endothelial function and methods of use thereof | Feb 11, 2020 | Issued |
Array
(
[id] => 16557180
[patent_doc_number] => 20210002328
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-07
[patent_title] => PEPTIDE THERAPIES FOR REDUCTION OF MACULAR THICKENING
[patent_app_type] => utility
[patent_app_number] => 16/750742
[patent_app_country] => US
[patent_app_date] => 2020-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16750742
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/750742 | Peptide therapies for reduction of macular thickening | Jan 22, 2020 | Issued |
Array
(
[id] => 15895309
[patent_doc_number] => 20200147173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE
[patent_app_type] => utility
[patent_app_number] => 16/738792
[patent_app_country] => US
[patent_app_date] => 2020-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16738792
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/738792 | BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE | Jan 8, 2020 | Abandoned |
Array
(
[id] => 17443709
[patent_doc_number] => 20220064214
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => NOVEL PEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/420927
[patent_app_country] => US
[patent_app_date] => 2020-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27925
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420927
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/420927 | NOVEL PEPTIDES AND USES THEREOF | Jan 5, 2020 | Pending |
Array
(
[id] => 15895327
[patent_doc_number] => 20200147182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
[patent_app_type] => utility
[patent_app_number] => 16/732545
[patent_app_country] => US
[patent_app_date] => 2020-01-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6630
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732545
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/732545 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY | Jan 1, 2020 | Abandoned |
Array
(
[id] => 17336050
[patent_doc_number] => 20220002381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => TACI-FC FUSION PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/052079
[patent_app_country] => US
[patent_app_date] => 2019-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4575
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052079
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/052079 | TACI-FC FUSION PROTEINS AND USES THEREOF | Dec 23, 2019 | Pending |
Array
(
[id] => 16482473
[patent_doc_number] => 20200376073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => METHOD OF TREATING LOW BLOOD PRESSURE
[patent_app_type] => utility
[patent_app_number] => 16/725319
[patent_app_country] => US
[patent_app_date] => 2019-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1779
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725319
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/725319 | METHOD OF TREATING LOW BLOOD PRESSURE | Dec 22, 2019 | Abandoned |
Array
(
[id] => 17414057
[patent_doc_number] => 20220048961
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => TRANSFERRIN RECEPTOR TARGETING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/312703
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 113090
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -71
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312703
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/312703 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | Dec 12, 2019 | Pending |
Array
(
[id] => 15990501
[patent_doc_number] => 20200171121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => CATIONIC ANTIMICROBIAL PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/712383
[patent_app_country] => US
[patent_app_date] => 2019-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12975
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712383
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/712383 | CATIONIC ANTIMICROBIAL PEPTIDES | Dec 11, 2019 | Abandoned |
Array
(
[id] => 17258478
[patent_doc_number] => 20210371463
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => Modified Netrin-1 Peptides and Compositions for Cardioprotection
[patent_app_type] => utility
[patent_app_number] => 17/286851
[patent_app_country] => US
[patent_app_date] => 2019-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9972
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 214
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286851
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/286851 | Modified Netrin-1 Peptides and Compositions for Cardioprotection | Dec 10, 2019 | Pending |
Array
(
[id] => 17312896
[patent_doc_number] => 20210401944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => COMPOSITION AND METHODS FOR REGULATING CHONDROCYTE PROLIFERATION AND INCREASING OF CARTILAGE MATRIX PRODUCTION
[patent_app_type] => utility
[patent_app_number] => 17/294079
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17042
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294079
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/294079 | COMPOSITION AND METHODS FOR REGULATING CHONDROCYTE PROLIFERATION AND INCREASING OF CARTILAGE MATRIX PRODUCTION | Nov 17, 2019 | Pending |
Array
(
[id] => 15960697
[patent_doc_number] => 20200164100
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 16/679881
[patent_app_country] => US
[patent_app_date] => 2019-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31384
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/679881 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS | Nov 10, 2019 | Pending |
Array
(
[id] => 15553141
[patent_doc_number] => 20200060982
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/668754
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 164
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668754
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/668754 | PURIFIED THERAPEUTIC NANOPARTICLES AND PREPARATION METHODS THEREOF | Oct 29, 2019 | Abandoned |
Array
(
[id] => 15708747
[patent_doc_number] => 20200101139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-02
[patent_title] => MEDICAMENT FOR MITIGATING CONDITIONS AND/OR SUPPRESSING ONSET OF PERIPHERAL NEUROPATHY INDUCED BY ANTI-MALIGNANT TUMOR AGENT
[patent_app_type] => utility
[patent_app_number] => 16/657507
[patent_app_country] => US
[patent_app_date] => 2019-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657507
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/657507 | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent | Oct 17, 2019 | Issued |
Array
(
[id] => 20272008
[patent_doc_number] => 12441777
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => GLP-1 receptor antagonists
[patent_app_type] => utility
[patent_app_number] => 17/284351
[patent_app_country] => US
[patent_app_date] => 2019-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 10394
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284351
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/284351 | GLP-1 receptor antagonists | Oct 13, 2019 | Issued |
Array
(
[id] => 18717873
[patent_doc_number] => 11795204
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Glucagon analogues
[patent_app_type] => utility
[patent_app_number] => 16/566992
[patent_app_country] => US
[patent_app_date] => 2019-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 12998
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566992
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/566992 | Glucagon analogues | Sep 10, 2019 | Issued |
Array
(
[id] => 17110136
[patent_doc_number] => 20210290733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => INJECTABLE MICRONIZED HUMAN INSULIN
[patent_app_type] => utility
[patent_app_number] => 17/259904
[patent_app_country] => US
[patent_app_date] => 2019-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2116
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259904
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/259904 | INJECTABLE MICRONIZED HUMAN INSULIN | Jul 10, 2019 | Abandoned |
Array
(
[id] => 14960629
[patent_doc_number] => 20190307792
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-10
[patent_title] => MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/449632
[patent_app_country] => US
[patent_app_date] => 2019-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16449632
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/449632 | Mineral salt-sulfonic acid compositions and methods of use | Jun 23, 2019 | Issued |